Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) COO Jeff E. Knight sold 32,359 shares of the firm’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $44.31, for a total value of $1,433,827.29. Following the transaction, the chief operating officer now owns 52,580 shares of the company’s stock, valued at $2,329,819.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Crinetics Pharmaceuticals Price Performance
Crinetics Pharmaceuticals stock opened at $44.43 on Thursday. Crinetics Pharmaceuticals, Inc. has a 1-year low of $15.23 and a 1-year high of $47.58. The stock has a market cap of $3.09 billion, a PE ratio of -12.01 and a beta of 0.62. The stock’s fifty day moving average is $39.56 and its two-hundred day moving average is $34.15.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 52.93% and a negative net margin of 4,223.27%. During the same period last year, the firm posted ($0.84) EPS. Crinetics Pharmaceuticals’s revenue was down 100.0% on a year-over-year basis. On average, research analysts expect that Crinetics Pharmaceuticals, Inc. will post -3.34 earnings per share for the current fiscal year.
Institutional Trading of Crinetics Pharmaceuticals
Analysts Set New Price Targets
CRNX has been the subject of a number of recent research reports. Citigroup initiated coverage on Crinetics Pharmaceuticals in a report on Wednesday, March 6th. They issued a “buy” rating and a $68.00 target price for the company. JMP Securities lifted their target price on Crinetics Pharmaceuticals from $60.00 to $80.00 and gave the company a “market outperform” rating in a report on Wednesday, March 20th. Jonestrading lifted their target price on Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. Jefferies Financial Group initiated coverage on Crinetics Pharmaceuticals in a report on Thursday, December 21st. They issued a “hold” rating and a $35.00 target price for the company. Finally, Cantor Fitzgerald lifted their target price on Crinetics Pharmaceuticals from $50.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, March 4th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.17.
Read Our Latest Research Report on Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Further Reading
- Five stocks we like better than Crinetics Pharmaceuticals
- What is a Death Cross in Stocks?
- Best Bear Market Funds: Top 3 Investment Options to Consider
- What Are the U.K. Market Holidays? How to Invest and Trade
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- How to Effectively Use the MarketBeat Ratings Screener
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.